Question · Q3 2026
Kenric Tyghe asked about Aurora Cannabis's strategic decision to exit select Canadian consumer cannabis markets, inquiring about the expected revenue run rate post-exit and the potential for a complete divestiture from the Canadian consumer segment. He also questioned the potential disruptiveness and timeline of the premiumization strategy for the Australian medical cannabis market and its anticipated benefits.
Answer
Miguel Martin, Executive Chairman and CEO, explained that the market exits are being evaluated for financial benefits, emphasizing the reallocation of high-quality flower to higher-margin international markets. He noted that a complete exit from Canadian consumer cannabis is under continuous evaluation, driven by profitability and growth objectives. Regarding Australia, Mr. Martin stated the premiumization strategy is not disruptive, as the market is expanding beyond value products, aligning with Aurora's global focus on core and premium medical cannabis offerings for better margins.
Ask follow-up questions
Fintool can predict
ACB's earnings beat/miss a week before the call